SUPPLEMENT

Q1 2026 — Financial disclosures

Q1 2026PDF · 9 pages1.1 MB
Merck & Co., Inc.,
Rahway, N.J., USA
Financial Highlights Package
First Quarter 2026
Table of Contents
Table 1: GAAP P&L....................................................................................1
Table 1a: GAAP P&L – Current Year and Prior Year by Quarter.................2
Table 2a: GAAP to Non-GAAP Reconciliation 1Q26....................................3
Table 2b: GAAP to Non-GAAP Reconciliation 1Q25....................................4
Table 3: Sales - Current Year and Prior Year by Quarter...........................5
Table 3a: Sales – U.S. / International 1Q26.................................................6
Table 3b: Sales – Pharmaceutical Geographic Split....................................7
Table 4: Other (Income) Expense .............................................................8

-- 1 of 9 --

Sales 	16,286	$ 	15,529	$ 	5%
Costs, Expenses and Other
Cost of sales 	4,195 	3,419 	23%
Selling, general and administrative 	2,700 	2,552 	6%
Research and development 	12,592 	3,621 	*
Restructuring costs 	195 	69 	*
Other (income) expense, net 	138 	(35) 	*
(Loss) Income Before Taxes 	(3,534) 	5,903 	*
Income Tax Provision 	709 	818
Net (Loss) Income 	(4,243) 	5,085 	*
Less: Net (Loss) Income Attributable to Noncontrolling Interests 	(3) 	6
Net (Loss) Income Attributable to Merck & Co., Inc., Rahway, N.J., USA 	(4,240)	$ 	5,079	$ 	*
(Loss) Earnings per Common Share Assuming Dilution (1) 	(1.72)	$ 	2.01	$ 	*
Average Shares Outstanding Assuming Dilution (1) 	2,472 	2,531
Tax Rate 	-20.1% 	13.9%
* 100% or greater
(1) Because the Company recorded a net loss in the first quarter of 2026, no potential dilutive common shares were used in the
computation of loss per common share assuming dilution as the effect would have been anti-dilutive.
MERCK & CO., INC., RAHWAY, N.J., USA
CONSOLIDATED STATEMENT OF OPERATIONS - GAAP
(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)
(UNAUDITED)
Table 1
GAAP
% Change
1Q26 	1Q25
1

-- 2 of 9 --

Sales 	16,286	$ 	15,529	$ 	15,806	$ 	17,276	$ 	16,400	$ 	65,011	$ 	5%
Costs, Expenses and Other
Cost of sales 	4,195 	3,419 	3,557 	3,855 	5,551 	16,382 	23%
Selling, general and administrative 	2,700 	2,552 	2,649 	2,633 	2,898 	10,733 	6%
Research and development 	12,592 	3,621 	4,048 	4,234 	3,886 	15,789 	*
Restructuring costs 	195 	69 	560 	47 	213 	889 	*
Other (income) expense, net 	138 	(35) 	(7) 	(238) 	432 	151 	*
(Loss) Income Before Taxes 	(3,534) 	5,903 	4,999 	6,745 	3,420 	21,067 	*
Income Tax Provision 	709 	818 	571 	958 	458 	2,804
Net (Loss) Income 	(4,243) 	5,085 	4,428 	5,787 	2,962 	18,263 	*
Less: Net (Loss) Income Attributable to Noncontrolling Interests 	(3) 	6 	1 	2 	(1) 	9
Net (Loss) Income Attributable to Merck & Co., Inc., Rahway, N.J., USA 	(4,240)	$ 	5,079	$ 	4,427	$ 	5,785	$ 	2,963	$ 	18,254	$ 	*
(Loss) Earnings per Common Share Assuming Dilution (1) 	(1.72)	$ 	2.01	$ 	1.76	$ 	2.32	$ 	1.19	$ 	7.28	$ 	*
Average Shares Outstanding Assuming Dilution (1) 	2,472 	2,531 	2,513 	2,498 	2,488 	2,507
Tax Rate 	-20.1% 	13.9% 	11.4% 	14.2% 	13.4% 	13.3%
* 100% or greater
Sum of quarterly amounts may not equal year-to-date amounts due to rounding.
MERCK & CO., INC., RAHWAY, N.J., USA
CONSOLIDATED STATEMENT OF OPERATIONS - GAAP
(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)
(UNAUDITED)
Table 1a
%
Change
4Q 	1Q	Full Year
2026
1Q 	1Q 	2Q 	3Q
2025
2

-- 3 of 9 --

First Quarter
Cost of sales 	4,195	$ 	1,014 	237 	1,251 	2,944	$
Selling, general and administrative 	2,700 	32 	32 	2,668
Research and development 	12,592 	34 	34 	12,558
Restructuring costs 	195 	195 	195 	–
Other (income) expense, net 	138 	(180) 	(180) 	318
Loss Before Taxes 	(3,534) 	(1,046) 	(466) 	180 	(1,332) 	(2,202)
Income Tax Provision (Benefit) 	709 	(202) (3) 	(85) (3) 	39 (3) 	(248) 	957
Net Loss 	(4,243) 	(844) 	(381) 	141 	(1,084) 	(3,159)
Net Loss Attributable to Merck & Co., Inc., Rahway, N.J., USA 	(4,240) 	(844) 	(381) 	141 	(1,084) 	(3,156)
Loss per Common Share Assuming Dilution (4) 	(1.72)	$ 	(0.34) 	(0.16) 	0.06 	(0.44) 	(1.28)	$
Tax Rate 	-20.1% 	-43.5%
Only the line items that are affected by non-GAAP adjustments are shown.
GAAP 	Acquisition- and Divestiture-
Related Costs (1) 	Restructuring Costs (2)	
(Income) Loss from
Investments in Equity
Securities
Adjustment Subtotal 	Non-GAAP
MERCK & CO., INC., RAHWAY, N.J., USA
FIRST QUARTER 2026 GAAP TO NON-GAAP RECONCILIATION
(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)
(UNAUDITED)
Table 2a
(4) Because the Company recorded a net loss in the first quarter of 2026, no potential dilutive common shares were used in the computation of loss per common share assuming dilution as the effect would have
been anti-dilutive.
The Company is providing certain non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and
trends. Management believes that providing non-GAAP information enhances investors’ understanding of the Company’s results because management uses non-GAAP measures to assess performance.
Management uses non-GAAP measures internally for planning and forecasting purposes and to measure the performance of the Company along with other metrics. In addition, annual employee compensation,
including senior management’s compensation, is derived in part using a non-GAAP pretax income metric. The non-GAAP information presented should be considered in addition to, but not as a substitute for or
superior to, information prepared in accordance with GAAP.
(1) Amounts included in cost of sales reflect expenses for the amortization of intangible assets, as well as the recognition of fair value step-up of inventories related to the 2025 Verona Pharma plc acquisition.
Amounts included in selling, general and administrative expenses reflect integration, transaction and certain other costs related to acquisitions and divestitures.
(2) Amounts primarily include employee separation costs, accelerated depreciation and asset impairment charges associated with facilities to be closed or divested, as well as contractual termination costs,
associated with activities under the Company's formal restructuring programs.
(3) Represents the estimated tax impacts on the reconciling items based on applying the statutory rate of the originating territory of the non-GAAP adjustments.
3

-- 4 of 9 --

First Quarter
Cost of sales 	3,419	$ 	620 	36 	656 	2,763	$
Selling, general and administrative 	2,552 	23 	23 	2,529
Research and development 	3,621 	7 	7 	3,614
Restructuring costs 	69 	69 	69 	–
Other (income) expense, net 	(35) 	(3) 	(107) 	(110) 	75
Income Before Taxes 	5,903 	(647) 	(105) 	107 	(645) 	6,548
Income Tax Provision (Benefit) 	818 	(117) (3) 	(18) (3) 	22 (3) 	(113) 	931
Net Income 	5,085 	(530) 	(87) 	85 	(532) 	5,617
Net Income Attributable to Merck & Co., Inc., Rahway, N.J., USA 	5,079 	(530) 	(87) 	85 	(532) 	5,611
Earnings per Common Share Assuming Dilution 	2.01	$ 	(0.21) 	(0.03) 	0.03 	(0.21) 	2.22	$
Tax Rate 	13.9% 	14.2%
Only the line items that are affected by non-GAAP adjustments are shown.
The Company is providing certain non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and trends.
Management believes that providing non-GAAP information enhances investors’ understanding of the Company’s results because management uses non-GAAP measures to assess performance. Management
uses non-GAAP measures internally for planning and forecasting purposes and to measure the performance of the Company along with other metrics. In addition, annual employee compensation, including senior
management’s compensation, is derived in part using a non-GAAP pretax income metric. The non-GAAP information presented should be considered in addition to, but not as a substitute for or superior to,
information prepared in accordance with GAAP.
(1) Amounts included in cost of sales primarily reflect expenses for the amortization of intangible assets. Amounts included in selling, general and administrative expenses reflect integration, transaction and certain
other costs related to acquisitions and divestitures. Amounts included in research and development expenses reflect the amortization of intangible assets.
(2) Amounts primarily include employee separation costs, accelerated depreciation and asset impairments associated with facilities to be closed or divested related to activities under the Company's formal
restructuring programs.
(3) Represents the estimated tax impacts on the reconciling items based on applying the statutory rate of the originating territory of the non-GAAP adjustments.
MERCK & CO., INC., RAHWAY, N.J., USA
FIRST QUARTER 2025 GAAP TO NON-GAAP RECONCILIATION
(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)
(UNAUDITED)
GAAP 	Acquisition- and Divestiture-
Related Costs (1) 	Restructuring Costs (2)	
(Income) Loss from
Investments in Equity
Securities
Table 2b
Adjustment Subtotal 	Non-GAAP
4

-- 5 of 9 --

MERCK & CO., INC., RAHWAY, N.J., USA
FRANCHISE / KEY PRODUCT SALES
(AMOUNTS IN MILLIONS)
(UNAUDITED)
Table 3
2026 	2025 	1Q
1Q 	1Q 	2Q 	3Q 	4Q 	Full Year 	Nom % 	Ex-Exch %
TOTAL SALES (1) 	$16,286 	$15,529 	$15,806 	$17,276 	$16,400 	$65,011 	5 	3
PHARMACEUTICAL 	14,349 	13,638 	14,050 	15,611 	14,843 	58,142 	5 	2
Oncology
Keytruda 	7,906 	7,205 	7,956 	8,142 	8,337 	31,641 	10 	6
Keytruda Qlex 	128 	5 	35 	40 	- 	-
Alliance Revenue – Lynparza (2) 	341 	312 	370 	379 	389 	1,450 	9 	6
Alliance Revenue – Lenvima (2) 	256 	258 	265 	258 	272 	1,053 	-1 	-2
Welireg 	199 	137 	162 	196 	220 	716 	45 	43
Alliance Revenue – Reblozyl (3) 	148 	119 	107 	136 	164 	525 	25 	25
Vaccines (4)
Gardasil/Gardasil 9 	1,069 	1,327 	1,126 	1,749 	1,031 	5,233 	-19 	-22
ProQuad/M-M-R II/Varivax 	538 	539 	609 	684 	619 	2,451 	- 	-2
RotaTeq 	206 	228 	121 	204 	119 	673 	-10 	-11
Vaxneuvance 	202 	230 	229 	226 	140 	825 	-12 	-16
Capvaxive 	142 	107 	129 	244 	279 	759 	33 	31
Enflonsia 	1 	79 	21 	100 	- 	-
Cardiometabolic & Respiratory
Winrevair 	525 	280 	336 	360 	467 	1,443 	88 	87
Ohtuvayre 	131 	178 	178 	- 	-
Alliance Revenue - Adempas/Verquvo (5) 	109 	106 	123 	112 	129 	470 	3 	3
Adempas (6) 	78 	68 	80 	82 	83 	312 	15 	5
Infectious Diseases
Bridion 	472 	441 	461 	439 	499 	1,841 	7 	7
Prevymis 	272 	208 	228 	266 	275 	978 	31 	26
Zerbaxa 	82 	70 	74 	81 	87 	312 	17 	14
Delstrigo 	75 	67 	83 	77 	79 	306 	12 	1
Isentress/Isentress HD 	59 	90 	86 	82 	67 	325 	-34 	-36
Dificid 	34 	83 	96 	43 	25 	247 	-59 	-59
Lagevrio 	28 	102 	83 	138 	57 	380 	-73 	-73
Diabetes
Januvia 	367 	549 	372 	382 	302 	1,604 	-33 	-33
Janumet 	207 	247 	251 	243 	199 	940 	-16 	-18
Other Pharmaceutical (7) 	774 	865 	703 	1,004 	770 	3,340 	-11 	-12
ANIMAL HEALTH 	1,791 	1,588 	1,646 	1,615 	1,505 	6,354 	13 	6
Livestock 	1,064 	924 	961 	1,023 	987 	3,896 	15 	8
Companion Animal 	727 	664 	685 	592 	518 	2,458 	9 	4
Other Revenues (8) 	146 	303 	110 	50 	52 	515 	-52 	4
Sum of quarterly amounts may not equal year-to-date amounts due to rounding.
(7) Includes Pharmaceutical products not individually shown above. Also reflects total alliance revenue for Koselugo of $161 million and $44
million in the first quarter of 2026 and 2025, respectively.
(8) Other Revenues are comprised primarily of revenues from third-party manufacturing arrangements and miscellaneous corporate revenues,
including revenue-hedging activities. Other Revenues related to the receipt of milestone payments for out-licensed products were $132 million
and $95 million in the first quarter of 2026 and 2025, respectively.
(1) Only select products are shown.
(2) Alliance Revenue represents the Company's share of profits, which are product sales net of cost of sales and commercialization costs.
(3) Alliance Revenue represents royalties.
(4) Total Vaccines sales were $2,314 million and $2,607 million in the first quarter of 2026 and 2025, respectively.
(5) Alliance Revenue represents the Company's share of profits from sales in Bayer's marketing territories, which are product sales net of cost of
sales and commercialization costs.
(6) Net product sales in the Company's marketing territories.
5

-- 6 of 9 --

MERCK & CO., INC., RAHWAY, N.J., USA
FRANCHISE / KEY PRODUCT SALES
FIRST QUARTER 2026
(AMOUNTS IN MILLIONS)
(UNAUDITED)
Table 3a
Global 	U.S. 	International
1Q 2026 	1Q 2025 	% Change 	1Q 2026 	1Q 2025 	% Change 	1Q 2026 	1Q 2025 	% Change
TOTAL SALES (1) 	$16,286 	$15,529 	5 	$9,164 	$8,522 	8 	$7,122 	$7,007 	2
PHARMACEUTICAL 	14,349 	13,638 	5 	8,512 	7,927 	7 	5,837 	5,711 	2
Oncology
Keytruda 	7,906 	7,205 	10 	4,599 	4,308 	7 	3,307 	2,897 	14
Keytruda Qlex 	128 	- 	106 	- 	21 	-
Alliance Revenue – Lynparza (2) 	341 	312 	9 	149 	145 	3 	192 	168 	15
Alliance Revenue – Lenvima (2) 	256 	258 	-1 	176 	186 	-5 	80 	72 	11
Welireg 	199 	137 	45 	152 	123 	24 	47 	15 	*
Alliance Revenue – Reblozyl (3) 	148 	119 	25 	128 	101 	27 	20 	18 	11
Vaccines (4)
Gardasil/Gardasil 9 	1,069 	1,327 	-19 	485 	536 	-10 	585 	790 	-26
ProQuad/M-M-R II/Varivax 	538 	539 	0 	409 	423 	-3 	129 	116 	11
RotaTeq 	206 	228 	-10 	165 	164 	0 	42 	64 	-35
Vaxneuvance 	202 	230 	-12 	123 	139 	-11 	78 	92 	-15
Capvaxive 	142 	107 	33 	118 	106 	11 	23 	1 	*
Enflonsia 	1 	- 	-1 	- 	3 	-
Cardiometabolic & Respiratory
Winrevair 	525 	280 	88 	477 	268 	78 	48 	12 	*
Ohtuvayre 	131 	- 	131 	-
Alliance Revenue - Adempas/Verquvo (5) 	109 	106 	3 	109 	97 	12 	9 	-100
Adempas (6) 	78 	68 	15 	78 	68 	15
Infectious Diseases
Bridion 	472 	441 	7 	427 	378 	13 	45 	63 	-29
Prevymis 	272 	208 	31 	135 	102 	32 	138 	106 	30
Zerbaxa 	82 	70 	17 	52 	42 	22 	30 	28 	9
Delstrigo 	75 	67 	12 	10 	15 	-34 	65 	52 	26
Isentress/Isentress HD 	59 	90 	-34 	35 	51 	-31 	24 	39 	-38
Dificid 	34 	83 	-59 	24 	72 	-67 	10 	11 	-10
Lagevrio 	28 	102 	-73 	16 	35 	-54 	12 	67 	-83
Diabetes
Januvia 	367 	549 	-33 	252 	344 	-27 	116 	204 	-43
Janumet 	207 	247 	-16 	68 	65 	5 	139 	182 	-23
Other Pharmaceutical (7) 	774 	865 	-11 	167 	227 	-26 	605 	637 	-5
ANIMAL HEALTH 	1,791 	1,588 	13 	519 	502 	3 	1,272 	1,086 	17
Livestock 	1,064 	924 	15 	211 	194 	9 	853 	730 	17
Companion Animal 	727 	664 	9 	308 	308 	0 	419 	356 	18
Other Revenues (8) 	146 	303 	-52 	133 	93 	43 	13 	210 	-94
*200% or greater
(6) Net product sales in the Company's marketing territories.
(7) Includes Pharmaceutical products not individually shown above. Also reflects total alliance revenue for Koselugo of $161 million and $44 million on a
global basis in the first quarter of 2026 and 2025, respectively.
(8) Other Revenues are comprised primarily of revenues from third-party manufacturing arrangements and miscellaneous corporate revenues, including
revenue-hedging activities. Other Revenues related to the receipt of milestone payments for out-licensed products were $132 million and $95 million in
the first quarter of 2026 and 2025, respectively.
Sum of U.S. plus international may not equal global due to rounding.
(1) Only select products are shown.
(2) Alliance Revenue represents the Company's share of profits, which are product sales net of cost of sales and commercialization costs.
(3) Alliance Revenue represents royalties.
(4) Total Vaccines sales were $2,314 million and $2,607 million on a global basis in the first quarter of 2026 and 2025, respectively.
(5) Alliance Revenue represents the Company's share of profits from sales in Bayer's marketing territories, which are product sales net of cost of sales and
commercialization costs.
6

-- 7 of 9 --

MERCK & CO., INC., RAHWAY, N.J., USA
PHARMACEUTICAL GEOGRAPHIC SALES
(AMOUNTS IN MILLIONS)
(UNAUDITED)
Table 3b
2026 	2025 	% Change
1Q 	1Q 	2Q 	3Q 	4Q 	Full Year 	1Q
TOTAL PHARMACEUTICAL 	$14,349 	$13,638 	$14,050 	$15,611 	$14,843 	$58,142 	5
United States 	8,512 	7,927 	8,328 	9,493 	8,662 	34,409 	7
% Pharmaceutical Sales 	59.3% 	58.1% 	59.3% 	60.8% 	58.4% 	59.2%
Europe (1) 	2,725 	2,384 	2,551 	2,675 	2,839 	10,449 	14
% Pharmaceutical Sales 	19.0% 	17.5% 	18.2% 	17.1% 	19.1% 	18.0%
Latin America 	624 	589 	654 	691 	644 	2,578 	6
% Pharmaceutical Sales 	4.3% 	4.3% 	4.7% 	4.4% 	4.3% 	4.4%
Asia Pacific (other than China and Japan) 	569 	535 	609 	593 	586 	2,323 	6
% Pharmaceutical Sales 	4.0% 	3.9% 	4.3% 	3.8% 	4.0% 	4.0%
Japan 	535 	651 	604 	693 	684 	2,632 	-18
% Pharmaceutical Sales 	3.7% 	4.8% 	4.3% 	4.4% 	4.6% 	4.5%
Eastern Europe/Middle East/Africa 	413 	435 	451 	365 	348 	1,598 	-5
% Pharmaceutical Sales 	2.9% 	3.2% 	3.2% 	2.3% 	2.3% 	2.7%
China (2) 	353 	668 	407 	377 	364 	1,816 	-47
% Pharmaceutical Sales 	2.5% 	4.9% 	2.9% 	2.4% 	2.5% 	3.1%
Canada 	137 	125 	135 	134 	153 	547 	9
% Pharmaceutical Sales 	1.0% 	0.9% 	1.0% 	0.9% 	1.0% 	0.9%
Other 	481 	324 	311 	590 	563 	1,790 	48
% Pharmaceutical Sales 	3.3% 	2.4% 	2.1% 	3.9% 	3.8% 	3.2%
Sum of quarterly amounts may not equal year-to-date amounts due to rounding.
(1) Europe represents all European Union countries, the European Union accession markets and the United Kingdom.
(2) Gardasil/Gardasil 9 sales in China were $0 million and $193 million in the first quarter of 2026 and 2025, respectively.
7

-- 8 of 9 --

OTHER (INCOME) EXPENSE, NET
1Q26 	1Q25
Interest income 	(35)	$ 	(109)	$
Interest expense 	479 	313
Exchange losses 	38 	90
Income from investments in equity securities, net (1) (168) 	(90)
Net periodic defined benefit plan (credit) cost other than service cost 	(134) 	(148)
Other, net 	(42) 	(91)
Total 	138	$ 	(35)	$
(1) Includes net realized and unrealized gains and losses from investments in equity securities either owned directly or through
ownership interests in investment funds. Unrealized gains and losses from investments that are directly owned are determined at
the end of the reporting period, while gains and losses from ownership interests in investment funds are accounted for on a one
quarter lag.
MERCK & CO., INC., RAHWAY, N.J., USA
OTHER (INCOME) EXPENSE, NET - GAAP
(AMOUNTS IN MILLIONS)
(UNAUDITED)
Table 4
8

-- 9 of 9 --